Literature DB >> 28752224

Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer's Disease.

Miren Ettcheto1,2,3,4, Sonia Abad1,3, Dmitry Petrov1,3, Ignacio Pedrós2,3, Oriol Busquets1,2,3,4, Elena Sánchez-López5,6, Gemma Casadesús7, Carlos Beas-Zarate8, Eva Carro3,9, Carme Auladell3,4,10, Jordi Olloquequi11, Merce Pallàs1,3,4, Jaume Folch2,3, Antoni Camins12,13,14,15.   

Abstract

The molecular basis of memory loss in Alzheimer's disease (AD), the main cause of senile dementia, is under investigation. In the present study, we have focused on the early hippocampal memory-related changes in APPswe/PS1dE9 (APP/PS1) mice, a well-established mouse model of familial AD. It is well known that molecules like cAMP response element binding (CREB) and binding protein (CBP) play a crucial role in memory consolidation. We analyzed CBP on its transcriptional activity and protein levels, finding a significant downregulation of both of them at 3-month-old mice. In addition, the downregulation of this molecule was associated with a decrease on acetylation levels of histone H3 in the hippocampus of APP/PS1 mice. Moreover, the p-CREB levels, which are important for memory acquisition at 3 months in APP/PS1 mice, were downregulated. Furthermore, we suggest that early neuroinflammation, especially due to the Tnfα gene increased expression, could also be responsible to this process of memory loss. Given all the previously mentioned results, we propose that an early suitable treatment to prevent the evolution of the disease should include a combination of drugs, including anti-inflammatories, which may decrease glial activation and Tnfα levels, and phosphodiesterase inhibitors that increase cAMP levels.

Entities:  

Keywords:  APPSwe/PS1dE9; Alzheimer disease; CBP; CREB; Hippocampus

Mesh:

Substances:

Year:  2017        PMID: 28752224     DOI: 10.1007/s12035-017-0690-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  67 in total

Review 1.  CBP/p300 in cell growth, transformation, and development.

Authors:  R H Goodman; S Smolik
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

2.  Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Authors:  Wei Zhang; Jian Hao; Rui Liu; Zhuo Zhang; Gesheng Lei; Changjun Su; Jianting Miao; Zhuyi Li
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

3.  Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice.

Authors:  Wei Zhang; Miao Bai; Ye Xi; Jian Hao; Zhuo Zhang; Changjun Su; Gesheng Lei; Jianting Miao; Zhuyi Li
Journal:  Neurobiol Aging       Date:  2012-01-25       Impact factor: 4.673

4.  Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains.

Authors:  Jian-Quan Shi; Wei Shen; Jun Chen; Bian-Rong Wang; Ling-Ling Zhong; Yin-Wei Zhu; Hai-Qing Zhu; Qiao-Quan Zhang; Ying-Dong Zhang; Jun Xu
Journal:  Brain Res       Date:  2010-10-21       Impact factor: 3.252

Review 5.  NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders.

Authors:  C Geoffrey Lau; R Suzanne Zukin
Journal:  Nat Rev Neurosci       Date:  2007-06       Impact factor: 34.870

6.  2016 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2016-04       Impact factor: 21.566

Review 7.  Neuroinflammation in Alzheimer's disease.

Authors:  Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

8.  Potential for primary prevention of Alzheimer's disease: an analysis of population-based data.

Authors:  Sam Norton; Fiona E Matthews; Deborah E Barnes; Kristine Yaffe; Carol Brayne
Journal:  Lancet Neurol       Date:  2014-08       Impact factor: 44.182

9.  The Alzheimer's disease beta-secretase enzyme, BACE1.

Authors:  Sarah L Cole; Robert Vassar
Journal:  Mol Neurodegener       Date:  2007-11-15       Impact factor: 14.195

Review 10.  Interactions between APP secretases and inflammatory mediators.

Authors:  Magdalena Sastre; Jochen Walter; Steve M Gentleman
Journal:  J Neuroinflammation       Date:  2008-06-18       Impact factor: 8.322

View more
  3 in total

1.  Chronic Hippocampal Expression of Notch Intracellular Domain Induces Vascular Thickening, Reduces Glucose Availability, and Exacerbates Spatial Memory Deficits in a Rat Model of Early Alzheimer.

Authors:  Pablo Galeano; María C Leal; Carina C Ferrari; María C Dalmasso; Pamela V Martino Adami; María I Farías; Juan C Casabona; Mariana Puntel; Sonia Do Carmo; Clara Smal; Martín Arán; Eduardo M Castaño; Fernando J Pitossi; A Claudio Cuello; Laura Morelli
Journal:  Mol Neurobiol       Date:  2018-03-26       Impact factor: 5.590

Review 2.  The Contribution and Therapeutic Potential of Epigenetic Modifications in Alzheimer's Disease.

Authors:  Ian C Wood
Journal:  Front Neurosci       Date:  2018-09-19       Impact factor: 4.677

3.  The CBP KIX domain regulates long-term memory and circadian activity.

Authors:  Snehajyoti Chatterjee; Christopher C Angelakos; Ethan Bahl; Joshua D Hawk; Marie E Gaine; Shane G Poplawski; Anne Schneider-Anthony; Manish Yadav; Giulia S Porcari; Jean-Christophe Cassel; K Peter Giese; Jacob J Michaelson; Lisa C Lyons; Anne-Laurence Boutillier; Ted Abel
Journal:  BMC Biol       Date:  2020-10-29       Impact factor: 7.364

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.